Antiviral gene known to block HIV also shows potent activity against SARS-CoV-2

New UB research reveals valuable information about the ways that host cells work to block entry of SARS-CoV-2 and, in turn, how the virus strikes back.

The findings uncover important features about cellular interactions between virus and host, and how they might be exploited to develop new methods of treatment for both SARS-CoV-2, the virus that causes COVID-19, and HIV.

The research was reported by virologists at the Jacobs School of Medicine and Biomedical Sciences at UB and published May 26 in Nature Communications.

“We are interested in understanding how host cells mount a defense against an invading viral pathogen,” says Spyridon Stavrou, assistant professor of microbiology and immunology in the Jacobs School and corresponding author on the paper.

The team focused on the host gene called Serine Incorporator 5 (SERINC5), which is potently antiviral toward HIV-1, the most prevalent form of the virus. They found that this gene also exhibits potent antiviral activity against SARS-CoV-2 and interestingly, it utilizes the same mechanism to block both SARS-CoV-2 and HIV.

“We were stunned that SERINC5 also blocks SARS-CoV-2, as this factor was primarily known to restrict retroviruses,” says Uddhav Timilsina, a postdoctoral researcher in the Stavrou lab and the first author of the study.

“The most surprising thing we observed is that SERINC5 uses a conserved mechanism to restrict both HIV-1 and SARS-CoV-2, viruses that are quite different and are responsible for current pandemics,” Stavrou says. “This shows a bona fide host-pathogen struggle and emphasizes the importance of SERINC5 as an antiviral gene.”

The UB researchers were also amazed by what they discovered about how the virus responds to SERINC5.

“Both HIV-1 and SARS-CoV-2 encode factors that counteract SERINC5 utilizing identical mechanisms,” Stavrou explains. “This again shows that SERINC5 is a very important antiviral host factor, as two very different viruses express viral factors — in the case of SARS-CoV-2 it’s an accessory protein called SARS-CoV-2 ORF7a — to thwart the antiviral effect mounted by the host cells.”

They report that this accessory protein expressed to fight SERINC5 works by blocking SERINC5 from getting incorporated inside the complete viral particles as they are produced and released from the infected cells.

“Therefore, in order to outwit the host intrinsic immune response, SARS-CoV-2 encodes an antiviral factor (ORF7a) to counteract SERINC5,” Stavrou says.   

The findings are beneficial for further studies on the biology of SARS-CoV-2, as the role of accessory proteins in the virus has not been well understood.

“Furthermore, the fact that SERINC5 acts on two very different viruses utilizing the same mechanism allows for targeting SERINC5 in the future for the development of therapeutics that may be good not just for SARS-CoV-2, but potentially for HIV-1,” he says.

He adds that the research demonstrates that antiviral mechanisms used by host genes are highly conserved, as many times host factors utilize the same mechanism to counteract very different viruses.

“It will be interesting to learn if the antiviral effect of SERINC5 extends to other viruses,” says Timilsina.

“Viruses and host are in this eternal arms race, in which both try to outwit one another,” Stavrou notes. “Understanding more about how that arms race works can only help us in our effort to blunt the effects of both the SARS-CoV-2 and HIV pandemics.”

Co-authors with Stavrou and Timilsina are Supawadee Umthong, postdoctoral fellow, and Emily B. Ivey and Brandon Waxman, doctoral candidates, all of the Department of Microbiology and Immunology.

The work was supported by the National Institutes of Health.